Sun pharma expects to stabilize India business in FY19

04 Oct 2018 Evaluate

Sun Pharmaceutical Industries is excepting its India business to stabilise in the current fiscal leading to reasonable volume growth since company has witnessing disruptions in 2017-18 due to Goods and Services Tax (GST) implementation. However, favorable demographics conditions will help the company to ensure reasonable volume growth in India.

Sun Pharmaceutical Industries is the world’s fourth largest specialty generic pharmaceutical company and India’s top pharmaceutical company.

Sun Pharma Inds. Share Price

1786.05 -40.05 (-2.19%)
10-Jan-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1786.05
Dr. Reddys Lab 1354.20
Cipla 1470.05
Lupin 2190.50
Zydus Lifesciences 1004.05
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.